Calcitonin given early to affect nerve pain after spinal cord injury
Tests calcitonin against placebo for nerve pain in adults with spinal cord injury.
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury
- Status
- Recruiting
- People taking part
- 126 people, planned
- Started
- 1 May 2023
- Expected to end
- 1 May 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Calcitonin
- Placebo
- Record updated
- 14 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a recent spinal cord injury. It tests whether early calcitonin lowers the chance or severity of nerve pain.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Spinal cord injury at any level and any degree of completeness, in the early stage after the injury.
- Earlier treatment
- People taking anticonvulsant (anti-seizure) medicines cannot join.
Main reasons for not taking part
- Taking anticonvulsant medicines
- Already having signs of nerve (neuropathic) pain
- Past allergic reaction to calcitonin
- Kidney, liver or heart problems, or neurological disorders
- Brain damage or major injury to the arms, legs or belly
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients aged ≥18 years, with spinal cord injury at any level and any degree of completeness in the early stage of trauma
Who cannot take part
- Intake of anticonvulsants medications
- Evidence of previous allergic reaction to calcitonin
- Patients with renal, hepatic and cardiac dysfunction or neurological disorders
- Evidence of neuropathic pain
- brain damage or major trauma to extremities or abdomen
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective randomized double blinded study will be conducted to evaluate the effect of early pharmacologic intervention with calcitonin on the incidence or the severity of neuropathic pain after spinal cord injury
The 2 groups in the trial
- Calcitonin groupTreatment being tested
patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.
Treatment: Calcitonin
- Placebo groupPlacebo, for comparison
patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury
- Plain-language title
- Calcitonin given early to affect nerve pain after spinal cord injuryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 14 May 2026